Grünenthal GmbH, a pharmaceutical company specialising in pain management, has appointed Jan Adams as chief commercial officer. Dr Adams was previously chief scientific officer at Grünenthal which he joined in 2017 and also served as head of strategy and portfolio. He has led Grünenthal’s R&D strategy and its development of a pipeline of treatments for acute and chronic pain, as well as Grünenthal's entry into the US market. Dr Adams is a doctor of medicine from Goethe University, Frankfurt, Germany. He succeeds Janneke van der Kamp who has been appointed chief executive officer at Norgine. Grünenthal is based in Aachen, Germany and its products are available in approximately 100 countries.
Grünenthal announced the appointment on 30 September 2024.
Copyright 2024 Evernow Publishing Ltd.